Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $15.88 USD
Change Today +0.41 / 2.65%
Volume 15.7K
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for astellas pharma inc-unsp adr (ALPMY)

Year over year, Astellas Pharma, Inc. has been able to grow revenues from ¥1.1T JPY to ¥1.2T JPY. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold from 29.00% to 26.71%. This was a driver that led to a bottom line growth from ¥90.9B JPY to ¥135.9B JPY.
View Income Statement In U.S. Dollar
Currency in
Millions of Japanese Yens
As of:Mar 31
Mar 31
Mar 31
Mar 31
4 Year
TOTAL REVENUES969,387.01,005,612.01,139,909.01,247,259.0
Cost of Goods Sold318,633.0324,127.0330,628.0333,197.0
GROSS PROFIT650,754.0681,485.0809,281.0914,062.0
Selling General & Admin Expenses, Total329,395.0345,663.0397,018.0452,522.0
R&D Expenses189,840.0181,955.0191,460.0206,594.0
Depreciation & Amortization, Total----36,000.038,664.0
Other Operating Expenses----11,820.017,146.0
OTHER OPERATING EXPENSES, TOTAL519,235.0527,618.0636,298.0714,926.0
OPERATING INCOME131,519.0153,867.0172,983.0199,136.0
Interest and Investment Income2,365.01,806.01,590.01,940.0
NET INTEREST EXPENSE2,365.01,806.01,590.01,940.0
Income (Loss) on Equity Investments194.033.01,451.0217.0
Currency Exchange Gains (Loss)1,005.01,464.0-8,019.0-3,568.0
Other Non-Operating Income (Expenses)8,271.0-2,402.0-460.0-467.0
EBT, EXCLUDING UNUSUAL ITEMS143,354.0154,768.0167,545.0197,258.0
Merger & Restructuring Charges-645.0------
Gain (Loss) on Sale of Investments2,716.05,428.08,586.02,540.0
Gain (Loss) on Sale of Assets-5,924.0-733.01,638.0214.0
Other Unusual Items, Total-12,427.0-34,790.0-55,795.0-10,329.0
Other Unusual Items-3,193.0------
EBT, INCLUDING UNUSUAL ITEMS127,074.0124,673.0121,974.0189,683.0
Income Tax Expense48,844.041,822.031,100.053,827.0
Earnings from Continuing Operations78,230.082,851.090,874.0135,856.0
NET INCOME78,230.082,851.090,874.0135,856.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS78,230.082,851.090,874.0135,856.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS78,230.082,851.090,874.0135,856.0

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPMY:US $15.88 USD +0.41

ALPMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $152.35 USD -0.08
Boston Scientific Corp $17.09 USD -0.02
CSL Ltd A$100.21 AUD -0.56
Mylan NV $54.67 USD -0.53
Solvay SA €121.10 EUR +0.75
View Industry Companies

Industry Analysis


Industry Average

Valuation ALPMY Industry Range
Price/Earnings 29.7x
Price/Sales 3.3x
Price/Book 3.2x
Price/Cash Flow 23.4x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC-UNSP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at